Plasma fibrin clot proteomics in patients with acute pulmonary embolism: Association with clot properties

Bryk, Agata Hanna; Natorska, Joanna; Ząbczyk, Michał; Zettl, K; Wiśniewski, Jacek R.; Undas, Anetta

doi:10.1016/j.jprot.2020.103946

Cited by 17 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is no compelling evidence for a link between altered fibrin clot properties and increased serum concentrations of apolipoproteins. Proteomic analysis of fibrin clots showed that apoB, E, A-I, and C-II were incorporated into plasma clots [14,31], which could affect fibrin clot structure [32]. We observed similar associations between serum apoB concentrations and both Ks and MaxAbs Lys50 , as well as between apoC-II and C-III and both MaxAbs CLT2018 and MaxAbs Lys50 in AS patients.…”

Section: Discussionsupporting

confidence: 63%

“…We did not perform the proteomic analysis of fibrin clots of AS patients to confirm the presence of apolipoproteins, however it is unlikely that in those subjects at similar lipid levels the results could be inconsistent in this regard. Moreover, we did not determine levels of other apolipoproteins, however their presence in proteomic analysis of plasma fibrin clots have been shown to be negligible [32,42]. Measurements of subfractions of LDL-C and HDL-C could have provided new insights but they were beyond the scope of the present study.…”

Section: Lipidsmentioning

confidence: 89%

See 1 more Smart Citation

Apolipoproteins and lipoprotein(a) as factors modulating fibrin clot properties in patients with severe aortic stenosis

et al. 2022

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 63%

Section: Lipidsmentioning

confidence: 89%

Apolipoproteins and lipoprotein(a) as factors modulating fibrin clot properties in patients with severe aortic stenosis

et al. 2022

Self Cite

View full text Add to dashboard Cite

“…Whereas clot lysis time (CLT) is the test that reflects the overall fibrinolytic activity of plasma. Increased CLT value is a manifestation of hypofibrinolysis and might predispose to both venous and arterial thrombosis [16,17].…”

Section: Introductionmentioning

confidence: 99%

Properties of Plasma Clots in Adult Patients Following Fontan Procedure: Relation to Clot Permeability and Lysis Time—Multicenter Study

Skubera

Gołąb

Plicner

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Objectives: thromboembolic complications are a major cause of morbidity and mortality following Fontan (FO) surgery. It is also well established that altered FO circulation results in systemic complications, including liver and endothelium damage. We sought to evaluate whether dysfunctions of these sources of hemostatic factors may result in changes of fibrin clot properties. Methods: a permeation coefficient (Ks) and clot lysis time (CLT) were assessed in 66 FO patients, aged 23.0 years [IQR 19.3–27.0], and 59 controls, aged 24.0 years [IQR 19.0–29.0]. Ks was determined using a pressure-driven system. CLT value was measured according to assay described by Pieters et al. Endothelium and liver-derived hemostatic factors along with liver function parameters were evaluated. The median time between FO operation and investigation was 20.5 years [IQR 16.3–22.0]. Results: FO patients had lower Ks (p = 0.005) and prolonged CLT (p < 0.001) compared to that of controls. Ks correlated with CLT (r = −0.28), FVIII (r = −0.30), FIX (r = −0.38), fibrinogen (r = −0.41), ALT (r = −0.25), AST (r = −0.26), GGTP (r = −0.27) and vWF antigen (r = −0.30), (all p < 0.05). CLT correlated with the time between FO operation and investigation (r = 0.29) and FIX (r = 0.25), (all p < 0.05). After adjustment for potential cofounders, TAFI antigen and GGTP were independent predictors of reduced Ks (OR 1.041 per 1% increase, 95% CI 1.009–1.081, p = 0.011 and OR 1.025 per 1 U/L increase, 95% CI 1.005–1.053, p = 0.033, respectively). Protein C and LDL cholesterol predicted prolonged CLT (OR 1.078 per 1% increase, 95% CI 1.027–1.153, p = 0.001 and OR 6.360 per 1 μmol/L increase, 95% CI 1.492–39.894, p = 0.011, respectively). Whereas elevated tPA was associated with lower risk of prolonged CLT (OR 0.550 per 1 ng/mL, 95% CI 0.314–0.854, p = 0.004). GGTP correlated positively with time between FO surgery and investigation (r = 0.25, p = 0.045) and patients with abnormal elevated GGTP activity (n = 28, 42.4%) had decreased Ks, compared to that of the others (5.9 × 10−9 cm2 vs. 6.8 × 10−9 cm2, p = 0.042). Conclusion: our study shows that cellular liver damage and endothelial injury were associated with prothrombotic clot phenotype reflected by Ks and CLT.

show abstract

“…Both tests are sensitive for levels and function of key proteins involved in clot formation and breakdown. [ 51 , 52 ] Historically, patients with cirrhosis were classified as hyperfibrinolytic. [ 53 ] A hyperfibrinolytic state in patients with cirrhosis has been linked to decreased levels of antiplasmin and thrombin-activatable fibrinolysis inhibitor or increased levels of tPA, and was described to potentially contribute to bleeding complications in these patients.…”

Section: Fibrinolysis and Permeability Of Fibrin Clots In Cirrhosismentioning

confidence: 99%

Fibrin clot properties and thrombus composition in cirrhosis

Driever

Lisman

2023

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Plasma fibrin clot proteomics in patients with acute pulmonary embolism: Association with clot properties

Cited by 17 publications

References 31 publications

Apolipoproteins and lipoprotein(a) as factors modulating fibrin clot properties in patients with severe aortic stenosis

Apolipoproteins and lipoprotein(a) as factors modulating fibrin clot properties in patients with severe aortic stenosis

Properties of Plasma Clots in Adult Patients Following Fontan Procedure: Relation to Clot Permeability and Lysis Time—Multicenter Study

Fibrin clot properties and thrombus composition in cirrhosis

Contact Info

Product

Resources

About